Radiopharmaceutical deals drive sector growth despite supply crisis
A reinvigorated interest in radiopharmaceuticals has brought nuclear medicine to the foreground with deals over 2024 further exemplifying this trend. As …
Post
-
-
Italian charity seeks EMA approval for rescued gene therapy
Italian research charity Telethon Foundation is one step closer to getting a gene therapy to treat rare disease Wiskott-Aldrich syndrome …
-
Thermo Fisher continues viral vector withdrawal; lays off 300 employees
Thermo Fisher is cutting the headcount at two of its US facilities by 300 as the company continues to overhaul …
-
USC receives grant for gene therapy targeting glioblastoma
The University of Southern California (USC) has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to …
-
Immunotherapeutic responses and their assessments
Immunotherapeutics have transformed the landscape of cancer outcomes. It is crucial that the atypical response patterns seen with them are …
-
World Cancer Day: WHO warns of rising cancer burden in Southeast Asia
The World Health Organization (WHO) has reported a significant increase in cancer cases across the Southeast Asia region, projecting an …
-
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 …
-
Microplastics: the silent threat
Microplastics, tiny plastic bits less than five millimetres in size, come from breaking down larger plastics and are now everywhere. …
-
AstraZeneca lung cancer therapy Imfinzi recommended for EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the …
-
People-focused cancer care demands policy support
Access to high-quality cancer care remains deeply uneven worldwide. While advances in cancer treatment and diagnostics are improving survival rates …
-
AdvanCell raises $112m as radiopharma buzz continues
AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector continues in 2025. The funding round …
-
MHRA seeks input on new regulatory guidance for cancer vaccines
The UK’s drug regulatory authority has launched a public consultation process to design a new regulatory guidance for personalised mRNA …
-
Pfizer’s colon cancer combo approval further supported by Phase III win
Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in …
-
Celltrion’s Avtozma receives FDA approval for multiple conditions
The US Food and Drug Administration (FDA) has granted approval for Celltrion's Avtozma (tocilizumab-anoh) in both intravenous and subcutaneous formulations …
-
Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchase
Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the …
